Skip to main content

Table 13 Physical characteristics of hepatitis C patients

From: Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs

 

Hepatitis C patients

 

Pre-dose values

Post-dose values

 

Parameters

Median (IQR)a

Median (IQR)

1

Subjects

 

Male (n)

8

8

 

Female (n)

6

6

 

Total (males + female)

14

14

2

Age (years)

44 (39–50)

44 (39–50)

 

Gender Male (%)

8 (57)

8 (57)

 

Gender Female (%)

6 (43)

6 (43)

3

Weight (kg)a

69 (64–72)

68 (52–70)

4

Height (cm)

169 (162–171)

169 (162–171)

5

BMI (kg/m2)

24 (23–25)

23 (22–24)

6

Pulse/minte

71 (68–79)

73 (70–77)

7

Temperature (°C)

37.4 (37.2–38.3)

37.5 (37.3–37.8)

8

Systolic blood pressure (mmHg)

125 (122–131)

120 (118–129)

 

Diastolic blood pressure (mmHg)

85 (80–90)

80 (75–85)

9

Heamoglobin (g/L)

142 (137–150)

143 (138–154)

10

Total Leukocytes counts (109/L)

5404 (4316–6505)

5385 (4523–7725)

11

Bilirubin (μmmol/L)

15 (11–22)

16 (10–20)

12

Alanine Aminotransferase (ALT; U/L)

68 (64–79)

60 (53–69)b

13

Aspartate Aminotransferase (AST; U/L)

56 (53–59)

48 (45–51)b

14

Alaline Phosphatase (ALP; U/L)

84 (72–91)

77 (68–85)b

15

Creatinine (μmol/L)

92 (84–109)

85 - (74–113)

  1. aIQR Interquartile Range (25–75); bWilcoxon Sinf rank test applied P < 0.001